NCT04816487

Brief Summary

Although black staining is considered a drawback that is clinically observed following SDF application and is the main primary barrier for its use clinically . Child's behaviour and cooperation cannot be controlled at a young age or in special health care needs cases. Therefore, the best treatment modality will always be a simple, fast and painless procedure and SDF is the best solution for those cases. Discolouration caused researchers to search for a solution that will reduce or prevent discolouration using KI and GSH. A systematic review was conducted in-vitro, and it showed the use of SDF with KI had reduced stains markedly, potential advantages of minimal staining might be advantageous, along a short period. However, studies with long-term follow-up would be required to provide evidence-based guidelines for using SDF and KI formulations in routine clinical practice

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 25, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2021

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
Last Updated

April 1, 2021

Status Verified

March 1, 2021

Enrollment Period

3 months

First QC Date

March 23, 2021

Last Update Submit

March 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Colour assessment

    Using Vita easy shade ( continuous) ΔE

    6 months

Secondary Outcomes (2)

  • Parenteral satisfaction

    6 months

  • 3-Side effects Gum swelling Gum bleaching Tooth or gum pain Nausea 3-Side effects Gum swelling Gum bleaching Tooth or gum pain Nausea 3-Side effects Gum swelling Gum bleaching Tooth or gum pain Nausea Side effects

    6 months

Study Arms (3)

Silver Diamine Flouride

ACTIVE COMPARATOR

Discoloration of primary carious teeth treated by SDF

Drug: Potassium Iodide or Glutathione

Glutathione

EXPERIMENTAL

Discoloration rate of primary carious teeth treated by SDF + Glutathione

Drug: Potassium Iodide or Glutathione

Potassium iodide

EXPERIMENTAL

Discoloration rate of primary carious teeth treated by SDF + KI

Drug: Potassium Iodide or Glutathione

Interventions

Patient will receive either Glutathione or Potassium iodide

GlutathionePotassium iodideSilver Diamine Flouride

Eligibility Criteria

Age3 Years - 5 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children:
  • Aged 3 to 5 years, in good general health and medically free.
  • The parents provided written informed consent.
  • Medically free
  • Teeth:
  • Carious primary teeth
  • Restorable teeth.
  • Teeth are not pulpally involved

You may not qualify if:

  • Children:
  • with a history of allergy to silver
  • Unable to attend follow-up visits.
  • Refusal of participation.
  • Teeth:
  • Previously restored teeth.
  • Periapical swelling and tenderness in this area.
  • With mobility.
  • With spontaneous pain.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Tooth Discoloration

Interventions

Potassium IodideGlutathione

Condition Hierarchy (Ancestors)

Tooth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

IodidesIodine CompoundsInorganic ChemicalsPotassium CompoundsOligopeptidesPeptidesAmino Acids, Peptides, and Proteins

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

March 23, 2021

First Posted

March 25, 2021

Study Start

May 1, 2021

Primary Completion

August 1, 2021

Study Completion

May 1, 2022

Last Updated

April 1, 2021

Record last verified: 2021-03